ArticleFrontline gastroenterology2021
Endoscopically delivered Purastat for the treatment of severe haemorrhagic radiation proctopathy: a service evaluation of a new endoscopic treatment for a challenging condition.
Article in Frontline gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Purastat therapy for bleeding radiation proctopathy.World journal of gastrointestinal endoscopy · 2026Article
- Review
- Hemostasis: Role of PuraStatWorld journal of gastrointestinal endoscopy · 2025Article
- Effective management of refractory haematuria using PuraStat: A case report and literature review.Urology case reports · 2025Article
- Self-Assembling Hemostatic Peptide Gel Used to Successfully Treat Rectal Ulcer in Radiation-Associated Vascular Ectasia: A Case Report.The American journal of case reports · 2025Article
- Post-polypectomy colorectal bleeding: current strategies and the way forward.Clinical endoscopy · 2025Review
- Efficacy of novel endoscopic hemostatic agent for bleeding control and prevention: Results from a prospective, multicenter national registry.Endoscopy international open · 2024Article
- Endoscopic techniques for management of large colorectal polyps, strictures and leaks.Surgery open science · 2024Article
- Systematic review of self-assembling peptides as topical agents for treatment and prevention of gastrointestinal bleeding.Clinical endoscopy · 2024Article
- Efficacy of a novel self-assembling peptide gel for hemostasis in refractory neoplastic bleeding.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2023Article
- Purastat as an Adjunct Treatment Option in Acute Esophageal Varices Bleeding: A Case Report.Cureus · 2023Article
- The Use of PuraStatMedicina (Kaunas, Lithuania) · 2023Article
- Clinical course and treatment of radiation-induced hemorrhagic gastritis: a case series study.Clinical journal of gastroenterology · 2023Article
- A case of gastric antral vascular ectasia in which PuraStat, a novel self-assembling peptide hemostatic hydrogel, was effective.DEN open · 2023Article
- Comparison of Endoscopic Hemostasis for Endoscopic Sphincterotomy Bleeding between a Novel Self-Assembling Peptide and Conventional Technique.Journal of clinical medicine · 2022Article
- Hemostatic powders for gastrointestinal bleeding: a review of old, new, and emerging agents in a rapidly advancing field.Endoscopy international open · 2022Review
- Clinical Use of the Self-Assembling Peptide RADA16: A Review of Current and Future Trends in Biomedicine.Frontiers in bioengineering and biotechnology · 2021Review
- A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA total of 30 000 people are treated with pelvic radiotherapy annually in the UK. Rectal bleeding is common following pelvic radiotherapy and one of the main causes is radiation proctopathy (RP). Six per cent develop severe bleeding from RP, leading to anaemia requiring iron +/- blood transfusion. There are very few safe, effective, evidence-based treatments. Purastat is a haemostatic agent licensed for gastrointestinal bleeding. It is a self-assembling peptide that forms a molecular mesh in contact with blood, thereby sealing blood vessels. There are numerous studies showing its efficacy and safety in various surgical/endoscopic settings. This service evaluation reports the first experience of the use of Purastat in RP.
methodsConsecutive patients attending pelvic radiation disease clinic with severe refractory RP were offered treatment with Purastat. This was defined as rectal bleeding into the pan±anaemia with no response to rectal sucralfate. Purastat was applied endoscopically at four weekly intervals up to three times, with more as required. Bleeding severity, endoscopic grade and haemoglobin were recorded.
resultsTwenty-one patients were treated (18 men, median age 76 years) with a median of three treatments. Ten were on antithrombotics, 1 had thrombocytopenia and 13 had anaemia at baseline. Median episodes of bleeding reduced from 4.5 (0-27) to 2 (0-16) in the 7 days prior to the first and third treatment, respectively. Endoscopic grade was improved. Mean haemoglobin increased from 116.0 to 122.7. There were no complications.
conclusionEven in this cohort of severe refractory RP, there was an improvement in bleeding and endoscopic grade with Purastat. A randomised controlled trial is planned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.